Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Immatics ( (IMTX) ) is now available.
On October 20, 2025, Immatics presented updated data from its ongoing Phase 1b trial of anzu-cel PRAME cell therapy in 16 patients with metastatic uveal melanoma. The trial data, with a cutoff on September 24, 2025, showed a confirmed objective response rate of 67% and a disease control rate of 88%. The median duration of response was 11 months, and the median progression-free survival was 8.5 months. The therapy demonstrated anti-tumor activity in liver and extrahepatic metastases, and maintained a favorable tolerability profile. Based on these promising results, Immatics has initiated a Phase 2 cohort to further explore anzu-cel’s potential in treating metastatic uveal melanoma.
The most recent analyst rating on (IMTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
Immatics’ overall stock score is primarily influenced by its financial performance and valuation challenges. The company faces significant profitability and cash flow issues, reflected in a low financial performance score. Technical analysis provides mixed signals, with no strong momentum in either direction. The negative P/E ratio highlights valuation concerns, further impacting the overall score.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics is a clinical-stage biopharmaceutical company and a global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. The company focuses on developing TCR T-cell therapies and TCR bispecifics, with a robust clinical pipeline that includes anzu-cel (IMA203) PRAME cell therapy.
Average Trading Volume: 833,330
Technical Sentiment Signal: Buy
Current Market Cap: $1.2B
For an in-depth examination of IMTX stock, go to TipRanks’ Overview page.